MedPath

Registry to Evaluate INOmax in Newborn Babies With Pulmonary Hypertension

Terminated
Conditions
Pulmonary Hypertension of Newborn
Interventions
Registration Number
NCT03132428
Lead Sponsor
Mallinckrodt
Brief Summary

Pulmonary hypertension is high blood pressure in the arteries to the lungs. It is a serious condition. It causes the blood vessels that carry blood from the heart to the lungs to become hard and narrow. When this happens, the heart has to work harder to pump the blood through.

Some babies are born with pulmonary hypertension (PH). Doctors might use INOmax (a gas the baby breathes) to help newborn babies (neonates) with PH. This study will use information from the records of registered babies to see how effective and safe INOmax is for treating premature and other newborn babies for up to 11 days after they are born.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
140
Inclusion Criteria
  1. Was either a P neonate born at least 27 weeks to less than 34 weeks of gestational age (GA) or a TNT neonate born at least 34 weeks but no more than 40 weeks of GA.
  2. Was administered INOmax therapy after birth to 7 days of age via any route (invasive or noninvasive ventilation) for a minimum treatment period of at least 24 hours up to 96 ± 12 hours. The participants may receive INOmax for a longer period.
  3. Had PH, as confirmed by echocardiogram or a differential saturation gradient of at least 10%.
  4. Received INOmax administration as part of routine clinical practice in a Level III or higher neonatal intensive care unit in the United States.
  5. Has all variables required to calculate OI or SOI (a baseline sample prior to treatment and 4 samples obtained during treatment).
Exclusion Criteria
  1. Was at risk of imminent death (death expected within 24 hours).
  2. Received extracorporeal membrane oxygenation (ECMO).
  3. Had a life-threatening abnormality (cranial, cardiac, thoracic), chromosomal abnormality, congenital diaphragmatic hernia, congenital heart defect (other than patent ductus arteriosus or small atrial septal defect).
  4. Had been resuscitated requiring chest compressions within 6 hours of receiving INOmax.
  5. Had Grade IV bilateral intraventricular hemorrhage or periventricular leukomalacia.
  6. Had active uncontrolled bleeding.
  7. Had disseminated intravascular coagulopathy.
  8. Had active seizures while receiving anticonvulsants.
  9. Experienced prolonged asphyxia with evidence of severe acidosis (pH < 7.25).
  10. Received concomitant pulmonary vasodilator therapy (eg, prostacyclin or sildenafil) except when sildenafil was used to wean the participant from INOmax therapy.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
P NeonatesINOmaxPremature (P) neonates \[at least 27 weeks but less than 34 weeks of gestational age\]
TNT NeonatesINOmaxTerm-Near-Term (TNT) neonates at least 34 weeks of gestational age
Primary Outcome Measures
NameTimeMethod
Number of neonates with significant response to INOmax treatment within each age groupwithin 108 hours

Significant response is defined as at least a 25% improvement from baseline in oxygenation index or surrogate oxygenation index (OI/SOI) during INOMAX treatment

Secondary Outcome Measures
NameTimeMethod
Number of neonates with significant response to Inomax treatment within each age group and severity groupwithin 108 hours

The severity of pulmonary hypertension (PH) is classified for each participant Categories: Mild, Moderate, Severe

Time to reach significant response to Inomax treatment within each age group and severity groupwithin 108 hours

The median time to INOmax complete response (25% improvement) for neonates with each baseline PH severity classification Categories: Mild, Moderate, Severe

Number of neonates with partial response to INOmax treatment within each age group and severity groupwithin 108 hours

Partial response is defined as less than a 25% improvement in OI/SOI during INOmax treatment

Trial Locations

Locations (30)

Loma Linda University Health Care

🇺🇸

Loma Linda, California, United States

University of Chicago Comer Children's Hospital

🇺🇸

Chicago, Illinois, United States

University of Pittsburgh Medical Center

🇺🇸

Pittsburgh, Pennsylvania, United States

Children's Hospital of New Jersey at Newark Beth Israel Medical Center

🇺🇸

Newark, New Jersey, United States

Nationwide Children's Hospital

🇺🇸

Columbus, Ohio, United States

University Hospitals Rainbow Babies & Children's Hospital

🇺🇸

Cleveland, Ohio, United States

University of Mississippi Medical Center

🇺🇸

Jackson, Mississippi, United States

Women & Infants Hospital of Rhode Island

🇺🇸

Providence, Rhode Island, United States

Cincinnati Children's Hospital Medical Center

🇺🇸

Cincinnati, Ohio, United States

University of Iowa Stead Family Children's Hospital

🇺🇸

Iowa City, Iowa, United States

Arkansas Children's Hospital Research Institute

🇺🇸

Little Rock, Arkansas, United States

Children's Hospital of Orange County

🇺🇸

Orange, California, United States

UCSF Benioff Children's Hospital

🇺🇸

San Francisco, California, United States

University of Minnesota Amplatz Children's Hospital

🇺🇸

Minneapolis, Minnesota, United States

Duke University

🇺🇸

Durham, North Carolina, United States

University of Texas Health Science Center at San Antonio

🇺🇸

San Antonio, Texas, United States

Banner Good Samaritan Medical Center

🇺🇸

Phoenix, Arizona, United States

Miller Children's and Women's Hospital - Long Beach

🇺🇸

Long Beach, California, United States

Florida Hospital for Children

🇺🇸

Orlando, Florida, United States

University of South Florida

🇺🇸

Tampa, Florida, United States

University of Kentucky Chandler

🇺🇸

Lexington, Kentucky, United States

Children's Mercy Hospital

🇺🇸

Kansas City, Missouri, United States

Saint Louis Children's Hospital

🇺🇸

Saint Louis, Missouri, United States

The Children's Hospital at OU Medical Center

🇺🇸

Oklahoma City, Oklahoma, United States

Children's Hospital of Philadelphia

🇺🇸

Philadelphia, Pennsylvania, United States

University of Texas Southwestern Medical Center

🇺🇸

Dallas, Texas, United States

Virginia Commonwealth University

🇺🇸

Richmond, Virginia, United States

Sharp Mary Birch Hospital for Women and Newborns

🇺🇸

San Diego, California, United States

Yale New Haven Children's Hospital

🇺🇸

New Haven, Connecticut, United States

Norton Children's Hospital

🇺🇸

Louisville, Kentucky, United States

© Copyright 2025. All Rights Reserved by MedPath